New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)
- SUNFISH Part 2 study population includes broad range of ages and disease severities, representing a real-world spectrum of people living with Type 2 or 3 SMA
- Evrysdi is the first and only at home SMA treatment approved by the FDA, and has proven efficacy across adults, children and infants 2 months and older
- More than 2,500 patients now treated with Evrysdi in clinical trial, compassionate use and real-world settings
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new exploratory 2-year longer-term data from Part 2 of SUNFISH, a global placebo-controlled study evaluating Evrysdi™ (risdiplam) in people aged 2-25 years with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA). The study suggests that gains in motor function observed with Evrysdi treatment at month 12 continued to improve or were maintained at month 24 across primary and secondary endpoint measures. Based on the natural history of the disease, people with Types 2 and 3 SMA who remain untreated decline in motor function over time. These data will be presented at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference taking place from March 15-18.
“These results build on the one-year findings from the SUNFISH trial and importantly show the durability of improvement or stabilization of motor function through two years of treatment,” said SUNFISH principal investigator Eugenio Mercuri, M.D., Ph.D., Department of Pediatric Neurology, Catholic University, Rome, Italy. “In addition, with no new safety signals identified, these second year results may support the favorable benefit-risk profile of Evrysdi over a longer period of time.”
Patients in SUNFISH Part 2 ranged in age from 2-25 and were treated with Evrysdi (n=120) or placebo and Evrysdi (n=60; patients in the placebo arm received placebo for 12 months followed by Evrysdi treatment for 12 months). The study evaluated a number of exploratory 24-month endpoints, which provide important insights into motor function and its impact on daily life. Findings demonstrated that Evrysdi:
- Maintained motor function improvements between months 12 and 24 as measured by Motor Function Measure (MFM-32)*.
- Increased motor function as measured by Revised Upper Limb Module (RULM)** and the Hammersmith Functional Motor Scale-Expanded (HFMSE)*** between months 12 and 24.
- Stabilized motor function for patients who began treatment with Evrysdi after 12 months of placebo as measured by MFM-32, RULM and HFMSE.
- Increased total score change from baseline, as measured by the caregiver-reported SMAIS**** upper limb module, and the patient-reported SMAIS score stabilized between months 12 and 24.
“These encouraging results confirm that the efficacy and safety of Evrysdi in people with Type 2 and Type 3 SMA can be sustained over time,” said Levi Garraway, M.D., Ph. D., Chief Medical Officer and Head of Global Product Development. “Therefore, these findings further highlight the potential longer-term benefit this first-of-its-kind medicine can have for people of varying ages and levels of SMA disease severity.”
Decreases in serious adverse events, high-grade adverse events and treatment-related adverse events were observed in the second year versus the first year in both treatment arms. The most common adverse events observed in the Evrysdi arm and the placebo and Evrysdi arm from 12-24 months were upper respiratory tract infection (15.8% and 10%, respectively), nasopharyngitis (21.7% and 16.7%, respectively), pyrexia (13.3% and 10%, respectively), headache (10% and 16.7%, respectively), diarrhea (7.5% and 10%, respectively), vomiting (11.7% and 13.3%, respectively) and cough (10% and 8.3%, respectively). The most common serious adverse events were pneumonia (6.7% and 0%, respectively) and influenza (0.8% and 0%, respectively).
Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.
About Evrysdi™ (risdiplam)
Evrysdi is a survival of motor neuron 2 (SMN2) splicing modifier designed to treat SMA by increasing and sustaining production of the survival of motor neuron (SMN) protein. SMN protein is found throughout the body and is critical for maintaining healthy motor neurons and movement. Evrysdi is administered daily at home in liquid form by mouth or by feeding tube.
The U.S. Food and Drug Administration (FDA) approved Evrysdi for the treatment of SMA in adults and children 2 months of age and older in August of 2020. In April, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Evrysdi for the treatment of 5q SMA in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. At this time, Evrysdi has been approved in seven countries and submitted in 57, including the EU 27 and Norway and Iceland.
Evrysdi is currently being evaluated in four multicenter trials in people with SMA:
- FIREFISH (NCT02913482) – an open-label, two-part pivotal clinical trial in infants with Type 1 SMA. Part 1 was a dose-escalation study in 21 infants with the primary objective of assessing the safety profile of Evrysdi in infants and determining the dose for Part 2. Part 2 is a pivotal, single-arm study of Evrysdi in 41 infants with Type 1 SMA treated for 2 years, followed by an open-label extension. Enrollment for Part 2 was completed in November 2018. The primary objective of Part 2 was to assess efficacy as measured by the proportion of infants sitting without support after 12 months of treatment, as assessed in the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development – Third Edition (BSID-III) (defined as sitting without support for 5 seconds). The study met its primary endpoint.
- SUNFISH (NCT02908685) – SUNFISH is a two-part, double-blind, placebo controlled pivotal study in people aged 2-25 years with Types 2 or 3 SMA. Part 1 (n=51) determined the dose for the confirmatory Part 2. Part 2 (n=180) evaluated motor function using total score of Motor Function Measure 32 (MFM-32) at 12 months. MFM-32 is a validated scale used to evaluate fine and gross motor function in people with neurological disorders, including SMA. The study met its primary endpoint.
- JEWELFISH (NCT03032172) – an open-label exploratory trial designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in people with SMA aged 6 months to 60 years who received other investigational or approved SMA therapies for at least 90 days prior to receiving Evrysdi. The study has completed recruitment (n=174).
- RAINBOWFISH (NCT03779334) – an open-label, single-arm, multicenter study, investigating the efficacy, safety, pharmacokinetics and pharmacodynamics of Evrysdi in babies (~n=25), from birth to six weeks of age (at first dose) with genetically diagnosed SMA who are not yet presenting with symptoms. The study is currently recruiting.
SMA is a severe, progressive neuromuscular disease that can be fatal. It affects approximately one in 10,000 babies and is the leading genetic cause of infant mortality. SMA is caused by a mutation of the survival motor neuron 1 (SMN1) gene, which leads to a deficiency of SMN protein. This protein is found throughout the body and is essential to the function of nerves that control muscles and movement. Without it, nerve cells cannot function correctly, leading to muscle weakness over time. Depending on the type of SMA, an individual’s physical strength and their ability to walk, eat or breathe can be significantly diminished or lost.
About Roche in Neuroscience
Neuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.
Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Duchenne muscular dystrophy and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
* MFM is a validated scale used to evaluate fine and gross motor function in people with neurological disorders, including SMA. It assesses 32 different motor functions from standing and walking through to use of hands and fingers.
** RULM is a scale designed to assess upper limb movement in people with SMA. It can capture progressive muscle weakness across the spectrum of the disease, reflective of the SUNFISH Part 2 study population.
*** HFMSE is intended to be used in assessing the functional motor abilities of people with SMA who are able to sit and walk.
**** SMAIS was developed to measure self-reported and caregiver-reported independence.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com
|Dr. Nicolas Dunant|
Phone: +41 61 687 05 17
Phone: +41 61 688 44 86
|Dr. Daniel Grotzky |
Phone: +41 61 688 31 10
Phone: +41 61 682 28 31
Phone: +41 79 327 54 74
Phone: +41 61 687 43 05
|Dr. Barbara von Schnurbein|
Phone: +41 61 687 89 67
|Roche Investor Relations|
|Dr. Karl Mahler|
Phone: +41 61 68-78503
|Jon Kaspar Bayard|
Phone: +41 61 68-83894
|Dr. Sabine Borngräber|
Phone: +41 61 68-88027
|Dr. Bruno Eschli|
Phone: +41 61 68-75284
|Dr. Birgit Masjost|
Phone: +41 61 68-84814
|Dr. Gerard Tobin|
Phone: +41 61 68-72942
|Investor Relations North America|
Phone: +1 650 225 3217
|Dr. Lisa Tuomi|
Phone: +1 650 467 8737
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Infant Bacterial Therapeutics receives additional patent protection in China15.4.2021 19:00:00 CEST | Press release
Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications for the invention are currently pending in additional important future markets including the US and Europe. IBT recently received similar patent protection in Japan. This patent increases the existing protection of IBTs drug candidate IBP-9414 in addition to Orphan Drug Exclusivity and biological data protection already established in the USA and EU. The Chinese patent expires in 2036 and the IBP-9414 product covered by this patent is intended to be mark
Infant Bacterial Therapeutics erhåller ytterligare patentskydd i Kina15.4.2021 19:00:00 CEST | Pressemelding
Infant Bacterial Therapeutics AB (IBT) tillkännager idag att det Kinesiska patentmyndigheten har beslutat utfärda ett godkännande av IBTs patentansökan: “A method of activating lactic acid bacteria”, vilket omfattar formuleringar av Lactobacillus reuteri inklusive IBP-9414. IBP-9414 är den läkemedelskandidat IBT utvecklar i fas III för förebyggande av nekrotiserande enterokolit hos prematura spädbarn och för förbättrat födointag hos dessa barn. Uppfinningen omfattar ett unikt sätt att aktivera bakterien och patentansökningar behandlas samtidigt i flera viktiga framtida marknader, inklusive USA och EU. IBT har sedan tidigare erhållit motsvarande patentskydd i Japan. Patentet styrker det existerande skyddet för IBTs läkemedelskandidat IBP-9414 för vilken både särläkemedelsstatus och dataskydd för biologiska produkter beviljats i USA och EU. Det kinesiska patentet sträcker sig till 2036 och IBP-9414 avses att marknadsföras i Kina när marknadsgodkännande erhållits. “Vi är mycket glada över
REPURCHASE OF SHARES15.4.2021 18:30:00 CEST | Press release
REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders N.V. (“Flow Traders”) (Euronext: FLOW) has successfully completed its share buyback programme. Flow Traders purchased 8,903 of its own shares on 15 April 2021 at an average price of €37.22 in accordance with the share buyback programme announced on 12 February 2021. These repurchases were made in order to satisfy the requirements of various employee incentive plans. The consideration of this purchase was €0.3 million. The total number of shares purchased under this programme is 725,577 shares at an average price of €34.45 for a total consideration of €25.0 million. 2,285,243 shares were held in treasury as at 15 April 2021. Contact Details Flow Traders N.V. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996799 Email: firstname.lastname@example.org About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Tr
Stolt-Nielsen Elects Janet Ashdown to Board of Directors15.4.2021 18:12:30 CEST | Press release
LONDON, April 15, 2021 - Stolt-Nielsen Limited (Oslo Børs: SNI) announced today that Janet Ashdown has been appointed to the Board of Directors of Stolt-Nielsen Limited. "Ms. Ashdown’s extensive industry experience, has given her good exposure to some of Stolt-Nielsen’s key markets. I am confident that she will bring constructive challenge and strategic insights to the Board," said CEO Niels G. Stolt-Nielsen. The Board of Directors of SNL received approval at the Company's Annual General Meeting held today to fill the vacancy. With the addition of Ms. Janet Ashdown, the Stolt-Nielsen Board now has eight members, five of which are independent. Ms. Ashdown is a highly-experienced Director and has served on the boards of four FTSE 250 companies across a broad range of industrial sectors. She joined BP plc in 1980, and during her 30 year career there had excellent exposure to some of Stolt-Nielsen’s key markets. In her last role with BP she was responsible for a £20bn network of fuel outle
Virbac: very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven by very solid performance in all areas15.4.2021 17:45:00 CEST | Press release
KEY FIGURESRevenue 1st quarter 2021 €266.5 millionGrowth at constant exchange rates and scope 1 +22.6% of which companion animals +25.1% food-producing animals +19.2%Growth at constant exchange rates +12.3% Total growth +7.6% +17.5%excl. Sentinel 1 Growth at constant exchange rates and scope is the organic growth of sales, excluding the impact of exchange rate changes, by calculating the indicator for the financial year in question and that for the previous financial year on the basis of identical exchange rates (the exchange rate used is that in effect for the previous financial year), and excluding the impact of changes in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year, and by excluding sales of Sentinel for the two financial years in question. Quarterly consolidated revenue Our revenue in the first quarter amounted to €266.5 million, with a substantial increase of +17.5% excluding Sent
NetJets Shares First Biannual Global Sustainability Program Progress Update15.4.2021 16:09:19 CEST | Press release
The World's Largest Private Aviation Company Furthers Its Commitment to Sustainable Aviation COLUMBUS, Ohio, April 15, 2021 (GLOBE NEWSWIRE) -- NetJets, the leader in private aviation with more than 760 aircraft worldwide, today releases its first biannual update following the launch of its expanded Global Sustainability Program in October 2020. Since the program announcement, NetJets has taken its commitment to sustainability a step further, acquiring a stake in WasteFuel®, a next generation waste-to-fuel business that transforms landfill waste into sustainable aviation fuel (SAF). NetJets will also purchase 100 million gallons of SAF over the next decade. This represents one of the largest SAF offtakes in the aviation industry and by far the largest in private aviation. In addition to sustainable fuel, NetJets’ initiative focuses on consumer and corporate carbon offsetting. This includes offsetting NetJets’ administrative and training flights, as well as its two corporate offices in
Rovio Entertainment's new team-based RPG Darkfire Heroes releases worldwide today on iOS and Android15.4.2021 15:00:00 CEST | Press release
Rovio’s new team-based RPG Darkfire Heroes releases worldwide today on iOS and Android Espoo, Finland – 15 April 2021 – Build a powerful party of heroes and embark on an adventure for the ages in Rovio Entertainment’s newest game, Darkfire Heroes. The game is available to download for free now worldwide on the App Store and Google Play after a successful soft launch period in select regions. Darkfire Heroes is a strategic team-based RPG set in a rich fantasy world. Players must assemble a powerful team of heroes to take on hordes of baddies. There is a collection of over 60 heroes at launch, each with their own unique style, abilities, and attacks. Choose the right heroes to take into battle, outfit them with powerful gear, and unleash powerful spells against enemies. There’s a substantial campaign for those looking for a single-player experience, but also a PvP arena for players that crave a bit of competition. A new IP in Rovio’s game portfolio, Darkfire Heroes is the first release f